Literature DB >> 29387883

NICE, the NHS, and Cancer Drugs.

Andrew Dillon1, Linda J Landells1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29387883     DOI： 10.1001/jama.2017.20552

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

Review 1.  Evaluation of technologies approved for supplemental payments in the United States.

Authors:  Timothy J Judson; Sanket S Dhruva; Rita F Redberg
Journal:  BMJ       Date:  2019-06-17

2.  Public values and plurality in health priority setting: What to do when people disagree and why we should care about reasons as well as choices.

Authors:  Rachel Baker; Helen Mason; Neil McHugh; Cam Donaldson
Journal:  Soc Sci Med       Date:  2021-04-02       Impact factor: 4.634

3.  EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.

Authors:  Rumona Dickson; Angela Boland; Rui Duarte; Eleanor Kotas; Nerys Woolacott; Robert Hodgson; Rob Riemsma; Sabine Grimm; Bram Ramaekers; Manuela Joore; Nasuh Büyükkaramikli; Eva Kaltenthaler; Matt Stevenson; Abdullah Pandor; Steve Edwards; Martin Hoyle; Jonathan Shepherd; Xavier Armoiry; Miriam Brazzelli
Journal:  Appl Health Econ Health Policy       Date:  2018-08       Impact factor: 2.561

Review 4.  Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma.

Authors:  Xavier Armoiry; Hans-Martin Spath; Aileen Clarke; Martin Connock; Paul Sutcliffe; Claude Dussart
Journal:  J Mark Access Health Policy       Date:  2019-07-30

5.  International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility.

Authors:  Jae Ho Jung; Dae Jung Kim; Kangho Suh; Jaeeun You; Je Ho Lee; Kyung In Joung; Dong Churl Suh
Journal:  Int J Environ Res Public Health       Date:  2021-01-14       Impact factor: 3.390
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.